Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
✍ Scribed by Cheng E. Chee; David P. Steensma; Wenting Wu; Curtis A. Hanson; Ayalew Tefferi
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 76 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In a retrospective study of 126 adult patients with French–American–British‐defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16–3,475; P = 0.24) or during follow‐up (median 1,108 ng/mL; range 238–43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000–5,000, or >5,000 ng/mL during follow‐up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in “good risk” myelodysplastic syndrome. Am. J. Hematol., 2008. © 2008 Wiley‐Liss, Inc.